Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese

Internal Medicine

Volumn 38, Issue 12, 1999, Pages 944-947

  Ishioka, Shinichi ^a   Hiyama, Keiko ^a   Sato, Hiroe ^a   Yamanishi, Yuji ^b   McLeod, Howard L ^c   Kumagai, Kazuhiko ^a   Maeda, Hiroyuki ^a   Yamakido, Michio ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b Hiroshima Memorial Hospital   (Japan)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Allele; Bone marrow toxicity; Rheumatic disease

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ALLELE; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; LEUKOPENIA; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

EID: 0033376417     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.944     Document Type: Article

References (13)

1. Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 6: 279-290, 1996.
2. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651-662, 1980.
3. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55: 15-20, 1994.
4. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 92: 949-953, 1995.
5. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 58: 694-702, 1996.
6. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126: 608-614, 1997.
7. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129: 716-718, 1998.
8. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 41: 1858-1866, 1998.
9. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 8: 367-370, 1999.
10. Collie-Duguid ESR, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9: 37-42, 1999.
11. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15: 17-30, 1996.
12. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 94: 6444-6449, 1997.
13. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 64: 46-51, 1998.